loading page

Survival and clinicopathological significance of CD47 in human solid tumors:an updated systematic reviews and meta-analysis
  • +5
  • Yongzhi Ye,
  • Meiqiong Chen,
  • Fada Ji,
  • Suicai Mi,
  • Zhixiong Chen,
  • Xiaowei Wu,
  • * Qiurong,
  • Xiaodong Liu
Yongzhi Ye
Traditional Chinese Hospital of Xiamen
Author Profile
Meiqiong Chen
The Affiliated Women and Children's Hospital of Xiamen University
Author Profile
Fada Ji
Traditional Chinese Hospital of Xiamen
Author Profile
Suicai Mi
Traditional Chinese Hospital of Xiamen
Author Profile
Zhixiong Chen
Traditional Chinese Hospital of Xiamen
Author Profile
Xiaowei Wu
Traditional Chinese Hospital of Xiamen
Author Profile
* Qiurong
Traditional Chinese Hospital of Xiamen
Author Profile
Xiaodong Liu
Traditional Chinese Hospital of Xiamen

Corresponding Author:yeah411327191@163.com

Author Profile

Abstract

Background: High expression levels of cluster of differentiation 47 (CD47) have been recognized as poor survival in several different cancers. Nevertheless, the significance of CD47 in patients with solid tumors remains controversial. Methods: This meta‑analysis was based on a search of PubMed, Embase and Web of Science databases to obtain 22 eligible published studies (totaling 4,204 patients) between January 2018 and January 2024. The combined hazard ratios (HRs) for overall survival (OS) were evaluated, and the HRs for relapse‑free survival (RFS), progression‑free survival (PFS), and disease‑free survival (DFS), as well as odds ratios for clinicopathological data, were also respectively combined. Results: The data obtained from these studies were extracted from these published studies and analyzed. This study suggested that CD47 overexpression was related to shorter OS times in human solid tumors, with a combined HR for OS (according to the univariate analysis) of HR=1.60 [95% confidence intervals (95% CI): 1.43‑1.79; P<0.00001], and a pooled HR for OS (according to the multivariate analysis) of HR=2.02 (95% CI: 1.43‑2.84; P<0.0001). The subgroup analysis revealed that CD47 overexpression was related with inferior OS rates according to country, cancer type, sample size, analysis type and the method via which the HR value was obtained (i.e., reported or extracted; P<0.05); in addition, a high expression level of CD47 was also a predictor of poor DFS, PFS and RFS rates (P<0.00001). Certain factors, such as lymph node metastasis, TNM staging, differentiation type, tumor recurrence and tobacco exposure, resulted in an upregulation of CD47 (P<0.05). Conclusion: CD47 overexpression was found to be significantly related with an advanced clinical stage, poor differentiation types and tobacco exposure, and may serve as a valuable biomarker for predicting worse prognosis in human solid tumors.
09 Jul 2024Submitted to Cancer Reports
11 Jul 2024Submission Checks Completed
11 Jul 2024Assigned to Editor
11 Jul 2024Review(s) Completed, Editorial Evaluation Pending
17 Jul 2024Reviewer(s) Assigned